Table. 1.

Summary of SARS-CoV-2 vaccine-induced immune responses among solid organ transplant recipients

Study Transplanted organ Vaccine Boosting number Outcome Demographic
Age (yr)a) Male (%)
Humoral response
Del Bello et al. (2022) [23] Kidney, liver, heart, lung, pancreas, combined BNT162b 3rd Anti-SARS-CoV-2 Ab: 67.9% positive rate 4 weeks after the 3rd dose 59±15 65.0
Hall et al. (2021) [24] Kidney, liver, heart, lung, pancreas, combined mRNA-1273 3rd Anti-RBD Ab: 55% positive rate 4 months after the 3rd dose 66.9 (64.0–71.8) 61.7
Memenga et al. (2023) [25] Heart BNT162, mRNA-1273 3rd Anti-SARS-CoV-2 IgG: 62.9% positive rate 1 month later the 3rd dose 55 (48.5–61) 69.0
Davidov et al. (2022) [28] Liver BNT162b 3rd Anti-RBD IgG: 98% positive rate 5 months after the 3rd dose 65 (52–70) 57.4
Perrier et al. (2022) [29] Kidney, liver, heart, lung 97% BNT162b 3rd, 4th Anti-RBD IgG: 67.6% positive rate 4 months after the 3rd dose and 76.2% positive rate 1 months after the 4th dose 61.2 (50.9–69.3) 66.7
Peled et al. (2022) [30] Heart BNT162b 4th Anti-RBD IgG Ab: 67.6% positive rate 2 weeks after the 4th dose 57.2±13.8 68.9
McAteer et al. (2024) [31] Liver, kidney, heart BNT162b 3rd Anti-SARS-CoV-2-Spike IgG: 100% positive rate 6 months after the 3rd dose and 94% positive rate 1 year after the 3rd dose 16 (13.8–17.0) 59.6
T cell response
Hall et al. (2021) [24] Kidney, liver, heart, lung, pancreas, combined mRNA-1273 3rd Increased SARS-CoV-2 specific T cell counts at 4 months after the 3rd dose with minimal polyfunctional CD8+ T cell response 66.9 (64.0–71.8) 61.7
Davidov et al. (2022) [28] Liver BNT162b 3rd Increased SARS-CoV-2 spike-specific T cell count 5 months after the 3rd dose 65 (52–70) 57.4
Müller et al. (2023) [32] Liver, kidney, pancreas BNT162b 3rd, 4th Increased Omicron spike-reactive CD4+ and CD8+ T cell responses after the 3rd and f4th doses with enriched TEMRA subset of CD8+ T cell NA 51.0
Harberts et al. (2022) [33] Liver BNT162b, mRNA-1273 3rd, 4th SARS-CoV-2 spike-specific T cell response: 72% positive rates 2 weeks after the 3rd dose and 60% positive rates 2 weeks after the 4th dose 59.0 (51.0–68.3) 60.4
Schrezenmeier et al. (2022) [34] Kidney BNT162b 4th Cellular responder with spike-specific CD4+ T cell response: 85% positive rates 1 month after the 4th dose 59.8±14.8 58.6

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Ab, antibody; IgG, immunoglobulin G; NA, not available.

a)Mean±standard deviation or median (interquartile range).

Clin Transplant Res 2024;38:247~256 https://doi.org/10.4285/ctr.24.0062